Patents by Inventor Claude L. Hughes, Jr.

Claude L. Hughes, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combined pharmaceutical estrogen-androgen-progestin
    Patent number: 6139873
    Abstract: Disclosed are methods and compositions for oral contraception and for hormone replacement therapy. Certain compositions of the invention contain androgens, preferably methyltestosterone to be taken in conjunction with estrogens and progestins.
    Type: Grant
    Filed: October 23, 1998
    Date of Patent: October 31, 2000
    Assignees: Cedars-Sinai Medical Center, Wake Forest University
    Inventors: Claude L. Hughes, Jr., Manuel J. Jayo
  • Prevention of ovarian cancer by administration of progestin products
    Patent number: 6028064
    Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: February 22, 2000
    Assignee: New Life Pharmaceuticals Inc.
    Inventors: Gustavo C. Rodriguez, Claude L. Hughes, Jr.
  • Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
    Patent number: 5962021
    Abstract: Disclosed are methods and compositions for oral contraception and hormonal therapy. Certain compositions and methods of the invention contain androgens, and preferably methyltestosterone to be combined with estrogen and progestin compositions in a hormonal component of a pharmaceutical composition.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: October 5, 1999
    Assignee: Wake Forest Universtiy
    Inventors: Claude L. Hughes, Jr., Manuel J. Jayo
  • Methods of treating or preventing endometriosis with phytoestrogens
    Patent number: 5942539
    Abstract: Methods of using phytoestrogens, in particular, isoflavones in the prevention and treatment of endometriosis and related disease conditions in females. One method comprises administering a therapeutically effective dosage of a phytoestrogen to females with endometriosis, females having symptoms related to endometriosis, or to females at risk of developing or suffering recurrence of endometriosis. In another method, at least one phytoestrogen may be administered singly or in combination with at least one hormonal therapeutic agent such as GnRH analogs, androgens, progestins, estrogens or any combination thereof. The therapeutically effective dosage of the phytoestrogen or the combination therapeutic ranges between about 25 and about 250 mg/day.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: August 24, 1999
    Assignee: Wake Forest University
    Inventors: Claude L. Hughes, Jr., J. Mark Cline, Thomas B. Clarkson, Daniel B. Whitesides
  • Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
    Patent number: 5770226
    Abstract: Disclosed are methods and compositions for oral contraception. Certain compositions of the invention contain androgens, preferably methyltestosterone to be taken by younger users of the contraceptives to inhibit adverse effects of oral contraceptive use on bone mineral density.
    Type: Grant
    Filed: July 10, 1996
    Date of Patent: June 23, 1998
    Assignee: Wake Forest University
    Inventors: Claude L. Hughes, Jr., Manuel J. Jayo